Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| ANAPTYSBIO, INCANAB · Entity 4640 | CHIEF FINANCIAL OFFICER | January 07, 2026 | January 10, 2026 |
| Arcturus Therapeutics Holdings Inc.ARCT · Entity 5523 | Chief Financial Officer | May 01, 2026 | May 07, 2026 |
| LA JOLLA PHARMACEUTICAL COLJPC · Entity 124310 | Chief Financial Officer | May 29, 2020 | June 02, 2020 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
ANAPTYSBIO, INC
Report date January 07, 2026 · Filed January 10, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 21,852 |
Ending reported balance
After 2026-01-08 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2026-01-07 · Exercise / conversion · Acquired 6,700 · Balance 24,367 F1: Each restricted stock unit ("RSU") represents a contingent right to receive 1 share of the Issuer's Common Stock upon settlement for no consideration. Row 2 · 2026-01-08 · Sale · Disposed 2,515 · Balance 21,852 F2: The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of RSUs. The sale was to satisfy tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person. |
| Restricted Stock UnitSEC Table II · derivative / convertible security | Direct | 20,100 |
Reported balance
After 2026-01-07 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2026-01-07 · Exercise / conversion · Disposed 6,700 · Balance 20,100 F1: Each restricted stock unit ("RSU") represents a contingent right to receive 1 share of the Issuer's Common Stock upon settlement for no consideration. F3: The RSUs vests as to 25% of the total RSUs annually commencing on January 7, 2026 until fully vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: Each restricted stock unit ("RSU") represents a contingent right to receive 1 share of the Issuer's Common Stock upon settlement for no consideration.
F2: The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of RSUs. The sale was to satisfy tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person.
F3: The RSUs vests as to 25% of the total RSUs annually commencing on January 7, 2026 until fully vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date.
Arcturus Therapeutics Holdings Inc.
Report date May 01, 2026 · Filed May 07, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Employee Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $8.63 · Expires 2036-05-01 | Direct | 100,000 |
Reported balance
After 2026-05-01 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-05-01 · Grant · Acquired 100,000 · Balance 100,000 F1: Represents options to purchase shares of common stock granted pursuant to the Company's Amended and Restated 2019 Omnibus Equity Incentive Plan, as amended. F2: The shares underlying this option vest 25% on May 1, 2027, the first anniversary of the date of grant, and the remainder vest in equal increments on each successive one-month anniversary thereafter for the next thirty-six months. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents options to purchase shares of common stock granted pursuant to the Company's Amended and Restated 2019 Omnibus Equity Incentive Plan, as amended.
F2: The shares underlying this option vest 25% on May 1, 2027, the first anniversary of the date of grant, and the remainder vest in equal increments on each successive one-month anniversary thereafter for the next thirty-six months.
LA JOLLA PHARMACEUTICAL CO
Report date May 29, 2020 · Filed June 02, 2020
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 5,067 |
Reported balance
After 2020-05-29 transaction · row 1
1 source rowRow 1 · 2020-05-29 · Grant · Acquired 82 · Balance 5,067 F1: These shares were acquired on 05/29/2020 through the La Jolla Pharmaceutical Company 2018 Employee Stock Purchase Plan in a transaction that was exempt under both Rule 16b-3(d) and Rule 16b-3(c). |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.72 · Expires 2030-05-29 | Direct | 82 |
Reported balance
After 2020-05-29 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2020-05-29 · Grant · Acquired 82 · Balance 82 F2: The stock option vests and becomes exercisable with respect to 25% of the underlying shares on the one-year anniversary of grant date and then vests and becomes exercisable ratably on a monthly basis over the next three years. |
Filing footnotes · ownership attribution and instrument terms
F1: These shares were acquired on 05/29/2020 through the La Jolla Pharmaceutical Company 2018 Employee Stock Purchase Plan in a transaction that was exempt under both Rule 16b-3(d) and Rule 16b-3(c).
F2: The stock option vests and becomes exercisable with respect to 25% of the underlying shares on the one-year anniversary of grant date and then vests and becomes exercisable ratably on a monthly basis over the next three years.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| May 01, 2026 Filed May 7, 2026 20:32 UTC | Arcturus Therapeutics Holdings Inc. ARCT · Entity 5523 | GrantEmployee Stock Option (right to buy) · Derivative | 100,000 | $0.00 Strike: $8.63 | $0.00 |
DisclosureSEC source: 0001193805-26-000578 · e665445_4-mulroy.xml · derivative · entry 1 MULROY DENNIS · CIK 0001276840 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 100,000 Underlying: Common Stock · 100,000 shares Expires 2036-05-01 F1 · shares: Represents options to purchase shares of common stock granted pursuant to the Company's Amended and Restated 2019 Omnibus Equity Incentive Plan, as amended. F2 · derivative.exercise_date: The shares underlying this option vest 25% on May 1, 2027, the first anniversary of the date of grant, and the remainder vest in equal increments on each successive one-month anniversary thereafter for the next thirty-six months. Read SEC document |
| January 08, 2026 Filed Jan 10, 2026 00:14 UTC | ANAPTYSBIO, INC ANAB · Entity 4640 | SaleCommon Stock | 2,515 | $44.71 | $112,445.65 |
DisclosureSEC source: 0001276840-26-000006 · form4-01102026_120148.xml · nonDerivative · entry 2 MULROY DENNIS · CIK 0001276840 · CHIEF FINANCIAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 21,852 F2 · kind: The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of RSUs. The sale was to satisfy tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person. Read SEC document |
| January 07, 2026 Filed Jan 8, 2026 21:08 UTC | ANAPTYSBIO, INC ANAB · Entity 4640 | SaleCommon Stock | 1,908 | $45.11 | $86,069.88 |
DisclosureSEC source: 0001276840-26-000004 · form4-01082026_090154.xml · nonDerivative · entry 2 MULROY DENNIS · CIK 0001276840 · CHIEF FINANCIAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 17,667 F2 · kind: The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of RSUs. The sale was to satisfy tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person. Read SEC document |
| January 07, 2026 Filed Jan 10, 2026 00:14 UTC | ANAPTYSBIO, INC ANAB · Entity 4640 | Exercise / conversionRestricted Stock Unit · Derivative | 6,700 | $0.00 | $0.00 |
DisclosureSEC source: 0001276840-26-000006 · form4-01102026_120148.xml · derivative · entry 3 MULROY DENNIS · CIK 0001276840 · CHIEF FINANCIAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 20,100 Underlying: Common Stock · 6,700 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive 1 share of the Issuer's Common Stock upon settlement for no consideration. F3 · derivative.exercise_date: The RSUs vests as to 25% of the total RSUs annually commencing on January 7, 2026 until fully vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date. F3 · derivative.expiration_date: The RSUs vests as to 25% of the total RSUs annually commencing on January 7, 2026 until fully vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date. Read SEC document |
| January 07, 2026 Filed Jan 10, 2026 00:14 UTC | ANAPTYSBIO, INC ANAB · Entity 4640 | Exercise / conversionCommon Stock | 6,700 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001276840-26-000006 · form4-01102026_120148.xml · nonDerivative · entry 1 MULROY DENNIS · CIK 0001276840 · CHIEF FINANCIAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 24,367 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit ("RSU") represents a contingent right to receive 1 share of the Issuer's Common Stock upon settlement for no consideration. Read SEC document |
| January 06, 2026 Filed Jan 8, 2026 21:08 UTC | ANAPTYSBIO, INC ANAB · Entity 4640 | GrantStock Option (right to buy) · Derivative | 29,000 | $0.00 Strike: $43.91 | $0.00 |
DisclosureSEC source: 0001276840-26-000004 · form4-01082026_090154.xml · derivative · entry 5 MULROY DENNIS · CIK 0001276840 · CHIEF FINANCIAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 29,000 Underlying: Common Stock · 29,000 shares Expires 2036-01-05 F5 · derivative.exercise_date: The stock option vests as to 25% of the total shares on January 6, 2027, and thereafter vests as to 1/48 of the total shares monthly until fully vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date. Read SEC document |
| January 06, 2026 Filed Jan 8, 2026 21:08 UTC | ANAPTYSBIO, INC ANAB · Entity 4640 | GrantRestricted Stock Unit · Derivative | 21,400 | $0.00 | $0.00 |
DisclosureSEC source: 0001276840-26-000004 · form4-01082026_090154.xml · derivative · entry 4 MULROY DENNIS · CIK 0001276840 · CHIEF FINANCIAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 21,400 Underlying: Common Stock · 21,400 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive 1 share of the Issuer's Common Stock upon settlement for no consideration. F4 · derivative.exercise_date: The RSUs vests as to 25% of the total RSUs annually commencing on January 6, 2027 until fully vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date. F4 · derivative.expiration_date: The RSUs vests as to 25% of the total RSUs annually commencing on January 6, 2027 until fully vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date. Read SEC document |
| January 06, 2026 Filed Jan 8, 2026 21:08 UTC | ANAPTYSBIO, INC ANAB · Entity 4640 | Exercise / conversionRestricted Stock Unit · Derivative | 5,245 | $0.00 | $0.00 |
DisclosureSEC source: 0001276840-26-000004 · form4-01082026_090154.xml · derivative · entry 3 MULROY DENNIS · CIK 0001276840 · CHIEF FINANCIAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,245 Underlying: Common Stock · 5,245 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive 1 share of the Issuer's Common Stock upon settlement for no consideration. F3 · derivative.exercise_date: The RSUs vests as to 25% of the total RSUs annually commencing on January 6, 2024 until fully vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date. F3 · derivative.expiration_date: The RSUs vests as to 25% of the total RSUs annually commencing on January 6, 2024 until fully vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date. Read SEC document |
| January 06, 2026 Filed Jan 8, 2026 21:08 UTC | ANAPTYSBIO, INC ANAB · Entity 4640 | Exercise / conversionCommon Stock | 5,245 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001276840-26-000004 · form4-01082026_090154.xml · nonDerivative · entry 1 MULROY DENNIS · CIK 0001276840 · CHIEF FINANCIAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 19,575 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit ("RSU") represents a contingent right to receive 1 share of the Issuer's Common Stock upon settlement for no consideration. Read SEC document |
| January 05, 2026 Filed Jan 7, 2026 02:05 UTC | ANAPTYSBIO, INC ANAB · Entity 4640 | SaleCommon Stock | 3,363 | $43.26 | $145,483.38 |
DisclosureSEC source: 0001276840-26-000002 · form4-01072026_020152.xml · nonDerivative · entry 2 MULROY DENNIS · CIK 0001276840 · CHIEF FINANCIAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 14,330 F2 · kind: The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of RSUs. The sale was to satisfy tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person. Read SEC document |
| January 03, 2026 Filed Jan 7, 2026 02:05 UTC | ANAPTYSBIO, INC ANAB · Entity 4640 | Exercise / conversionRestricted Stock Unit · Derivative | 8,292 | $0.00 | $0.00 |
DisclosureSEC source: 0001276840-26-000002 · form4-01072026_020152.xml · derivative · entry 3 MULROY DENNIS · CIK 0001276840 · CHIEF FINANCIAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 16,585 Underlying: Common Stock · 8,292 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive 1 share of the Issuer's Common Stock upon settlement for no consideration. F3 · derivative.exercise_date: The RSUs vests as to 25% of the total RSUs annually commencing on January 3, 2025 until fully vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date. F3 · derivative.expiration_date: The RSUs vests as to 25% of the total RSUs annually commencing on January 3, 2025 until fully vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date. Read SEC document |
| January 03, 2026 Filed Jan 7, 2026 02:05 UTC | ANAPTYSBIO, INC ANAB · Entity 4640 | Exercise / conversionCommon Stock | 8,292 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001276840-26-000002 · form4-01072026_020152.xml · nonDerivative · entry 1 MULROY DENNIS · CIK 0001276840 · CHIEF FINANCIAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 17,693 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit ("RSU") represents a contingent right to receive 1 share of the Issuer's Common Stock upon settlement for no consideration. Read SEC document |
| December 22, 2025 Filed Dec 23, 2025 21:28 UTC | ANAPTYSBIO, INC ANAB · Entity 4640 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 10,000 | $0.00 Strike: $20.16 | $0.00 |
DisclosureSEC source: 0001276840-25-000004 · form4-12232025_091206.xml · derivative · entry 3 MULROY DENNIS · CIK 0001276840 · CHIEF FINANCIAL OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 60,600 Underlying: Common Stock · 10,000 shares Expires 2030-07-12 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The stock option is fully vested. F3 · balance_after: In addition to the remaining options to purchase 60,600 shares of common stock as set forth in Table II, the Reporting Person also holds additional options to purchase up to an aggregate of 339,440 shares of common stock, which options vest according to their terms. Read SEC document |
| December 22, 2025 Filed Dec 23, 2025 21:28 UTC | ANAPTYSBIO, INC ANAB · Entity 4640 | SaleCommon Stock | 10,000 | $50.00 | $500,000.00 |
DisclosureSEC source: 0001276840-25-000004 · form4-12232025_091206.xml · nonDerivative · entry 2 MULROY DENNIS · CIK 0001276840 · CHIEF FINANCIAL OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 9,401 F1 · kind: The sale reported on this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on April 11, 2025. Read SEC document |
| December 22, 2025 Filed Dec 23, 2025 21:28 UTC | ANAPTYSBIO, INC ANAB · Entity 4640 | Exercise / conversionCommon Stock | 10,000 | $20.16 | $201,600.00 |
DisclosureSEC source: 0001276840-25-000004 · form4-12232025_091206.xml · nonDerivative · entry 1 MULROY DENNIS · CIK 0001276840 · CHIEF FINANCIAL OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 19,401 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 16, 2025 Filed Dec 18, 2025 21:13 UTC | ANAPTYSBIO, INC ANAB · Entity 4640 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 10,000 | $0.00 Strike: $20.16 | $0.00 |
DisclosureSEC source: 0001276840-25-000003 · form4-12182025_091222.xml · derivative · entry 4 MULROY DENNIS · CIK 0001276840 · CHIEF FINANCIAL OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 70,600 Underlying: Common Stock · 10,000 shares Expires 2030-07-12 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: The stock option is fully vested. F6 · balance_after: In addition to the remaining options to purchase 70,600 shares of common stock as set forth in Table II, the Reporting Person also holds additional options to purchase up to an aggregate of 339,440 shares of common stock, which options vest according to their terms. Read SEC document |
| December 16, 2025 Filed Dec 18, 2025 21:13 UTC | ANAPTYSBIO, INC ANAB · Entity 4640 | SaleCommon Stock | 6,360 | $45.21 | $287,511.43 |
DisclosureSEC source: 0001276840-25-000003 · form4-12182025_091222.xml · nonDerivative · entry 3 MULROY DENNIS · CIK 0001276840 · CHIEF FINANCIAL OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 9,401 F2 · kind: The sale reported on this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on April 11, 2025. F4 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $45.065 to $45.32 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| December 16, 2025 Filed Dec 18, 2025 21:13 UTC | ANAPTYSBIO, INC ANAB · Entity 4640 | SaleCommon Stock | 9,365 | $44.62 | $417,821.35 |
DisclosureSEC source: 0001276840-25-000003 · form4-12182025_091222.xml · nonDerivative · entry 2 MULROY DENNIS · CIK 0001276840 · CHIEF FINANCIAL OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 15,761 F2 · kind: The sale reported on this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on April 11, 2025. F3 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $44.07 to $45.05 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| December 16, 2025 Filed Dec 18, 2025 21:13 UTC | ANAPTYSBIO, INC ANAB · Entity 4640 | Exercise / conversionCommon Stock | 10,000 | $20.16 | $201,600.00 |
DisclosureSEC source: 0001276840-25-000003 · form4-12182025_091222.xml · nonDerivative · entry 1 MULROY DENNIS · CIK 0001276840 · CHIEF FINANCIAL OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 25,126 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Reflects the acquisition of 1,324 shares acquired under the Company's ESPP. Read SEC document |
| January 07, 2025 Filed Jan 7, 2025 22:32 UTC | ANAPTYSBIO, INC ANAB · Entity 4640 | GrantStock Option (right to buy) · Derivative | 76,400 | $0.00 Strike: $14.83 | $0.00 |
DisclosureSEC source: 0001415889-25-001044 · form4-01072025_100138.xml · derivative · entry 8 MULROY DENNIS · CIK 0001276840 · CHIEF FINANCIAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 76,400 Underlying: Common Stock · 76,400 shares Expires 2035-01-06 F8 · derivative.exercise_date: The stock option vests as to 25% of the total shares on January 7, 2026, and thereafter vests as to 1/48 of the total shares monthly until fully vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date. Read SEC document |
| January 07, 2025 Filed Jan 7, 2025 22:32 UTC | ANAPTYSBIO, INC ANAB · Entity 4640 | GrantRestricted Stock Unit · Derivative | 26,800 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-25-001044 · form4-01072025_100138.xml · derivative · entry 7 MULROY DENNIS · CIK 0001276840 · CHIEF FINANCIAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 26,800 Underlying: Common Stock · 26,800 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive 1 share of the Issuer's Common Stock upon settlement for no consideration. F7 · derivative.exercise_date: The RSUs vests as to 25% of the total RSUs annually commencing on January 7, 2026 until fully vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date. F7 · derivative.expiration_date: The RSUs vests as to 25% of the total RSUs annually commencing on January 7, 2026 until fully vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date. Read SEC document |
| January 06, 2025 Filed Jan 7, 2025 22:32 UTC | ANAPTYSBIO, INC ANAB · Entity 4640 | Exercise / conversionRestricted Stock Unit · Derivative | 5,245 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-25-001044 · form4-01072025_100138.xml · derivative · entry 6 MULROY DENNIS · CIK 0001276840 · CHIEF FINANCIAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,490 Underlying: Common Stock · 5,245 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive 1 share of the Issuer's Common Stock upon settlement for no consideration. F6 · derivative.exercise_date: The RSUs vests as to 25% of the total RSUs annually commencing on January 6, 2024 until fully vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date. F6 · derivative.expiration_date: The RSUs vests as to 25% of the total RSUs annually commencing on January 6, 2024 until fully vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date. Read SEC document |
| January 06, 2025 Filed Jan 7, 2025 22:32 UTC | ANAPTYSBIO, INC ANAB · Entity 4640 | Tax withholdingCommon Stock | 2,054 | $15.30 | $31,426.20 |
DisclosureSEC source: 0001415889-25-001044 · form4-01072025_100138.xml · nonDerivative · entry 4 MULROY DENNIS · CIK 0001276840 · CHIEF FINANCIAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 13,802 F3 · shares: Represents shares withheld by the Issuer to satisfy a portion of the tax withholding obligation in connection with the vesting of RSUs and do not represent discretionary transactions by the Reporting Person. Following the transactions reflecting in this Form 4, no additional transactions are expected to satisfy the Reporting Person's tax withholding obligation. F4 · shares: The Reporting Person did not sell or otherwise dispose of any of the shares with respect to the vesting of RSUs reported on this Form 4 for any reason other than to cover required taxes. Read SEC document |
| January 06, 2025 Filed Jan 7, 2025 22:32 UTC | ANAPTYSBIO, INC ANAB · Entity 4640 | Exercise / conversionCommon Stock | 5,245 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001415889-25-001044 · form4-01072025_100138.xml · nonDerivative · entry 3 MULROY DENNIS · CIK 0001276840 · CHIEF FINANCIAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 15,856 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit ("RSU") represents a contingent right to receive 1 share of the Issuer's Common Stock upon settlement for no consideration. Read SEC document |
| January 03, 2025 Filed Jan 7, 2025 22:32 UTC | ANAPTYSBIO, INC ANAB · Entity 4640 | Exercise / conversionRestricted Stock Unit · Derivative | 8,293 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-25-001044 · form4-01072025_100138.xml · derivative · entry 5 MULROY DENNIS · CIK 0001276840 · CHIEF FINANCIAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 24,877 Underlying: Common Stock · 8,293 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive 1 share of the Issuer's Common Stock upon settlement for no consideration. F5 · derivative.exercise_date: The RSUs vests as to 25% of the total RSUs annually commencing on January 3, 2025 until fully vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date. F5 · derivative.expiration_date: The RSUs vests as to 25% of the total RSUs annually commencing on January 3, 2025 until fully vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date. Read SEC document |
| January 03, 2025 Filed Jan 7, 2025 22:32 UTC | ANAPTYSBIO, INC ANAB · Entity 4640 | Tax withholdingCommon Stock | 3,407 | $14.60 | $49,742.20 |
DisclosureSEC source: 0001415889-25-001044 · form4-01072025_100138.xml · nonDerivative · entry 2 MULROY DENNIS · CIK 0001276840 · CHIEF FINANCIAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,611 F3 · shares: Represents shares withheld by the Issuer to satisfy a portion of the tax withholding obligation in connection with the vesting of RSUs and do not represent discretionary transactions by the Reporting Person. Following the transactions reflecting in this Form 4, no additional transactions are expected to satisfy the Reporting Person's tax withholding obligation. F4 · shares: The Reporting Person did not sell or otherwise dispose of any of the shares with respect to the vesting of RSUs reported on this Form 4 for any reason other than to cover required taxes. Read SEC document |
| January 03, 2025 Filed Jan 7, 2025 22:32 UTC | ANAPTYSBIO, INC ANAB · Entity 4640 | Exercise / conversionCommon Stock | 8,293 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001415889-25-001044 · form4-01072025_100138.xml · nonDerivative · entry 1 MULROY DENNIS · CIK 0001276840 · CHIEF FINANCIAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 14,018 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit ("RSU") represents a contingent right to receive 1 share of the Issuer's Common Stock upon settlement for no consideration. F2 · balance_after: Reflects the acquisition of 981 shares acquired under the Company's ESPP. Read SEC document |
| September 16, 2024 Filed Sep 17, 2024 22:41 UTC | ANAPTYSBIO, INC ANAB · Entity 4640 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 10,000 | $0.00 Strike: $20.16 | $0.00 |
DisclosureSEC source: 0001415889-24-023549 · form4-09172024_100933.xml · derivative · entry 6 MULROY DENNIS · CIK 0001276840 · CHIEF FINANCIAL OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 80,600 Underlying: Common Stock · 10,000 shares Expires 2030-07-12 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: The stock option vests and becomes exercisable as to 25% of the shares subject to the option on July 15, 2021, and thereafter vests as to 1/48th of the shares in equal monthly installments, until such time as the option is 100% vested, subject to the continuing employment of the Reporting Person on each vesting date. F6 · balance_after: In addition to the remaining options to purchase 80,600 shares of common stock as set forth in Table II, the Reporting Person also holds additional options to purchase up to an aggregate of 263,040 shares of common stock, which options vest according to their terms. Read SEC document |
| September 16, 2024 Filed Sep 17, 2024 22:41 UTC | ANAPTYSBIO, INC ANAB · Entity 4640 | SaleCommon Stock | 10,000 | $40.13 | $401,300.00 |
DisclosureSEC source: 0001415889-24-023549 · form4-09172024_100933.xml · nonDerivative · entry 4 MULROY DENNIS · CIK 0001276840 · CHIEF FINANCIAL OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 4,744 F3 · kind: The transactions reported on this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the reporting person dated June 14, 2024. Read SEC document |
| September 16, 2024 Filed Sep 17, 2024 22:41 UTC | ANAPTYSBIO, INC ANAB · Entity 4640 | Exercise / conversionCommon Stock | 10,000 | $20.16 | $201,600.00 |
DisclosureSEC source: 0001415889-24-023549 · form4-09172024_100933.xml · nonDerivative · entry 3 MULROY DENNIS · CIK 0001276840 · CHIEF FINANCIAL OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 14,744 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| September 16, 2024 Filed Sep 17, 2024 22:41 UTC | ANAPTYSBIO, INC ANAB · Entity 4640 | SaleCommon Stock | 2,220 | $38.93 | $86,424.60 |
DisclosureSEC source: 0001415889-24-023549 · form4-09172024_100933.xml · nonDerivative · entry 2 MULROY DENNIS · CIK 0001276840 · CHIEF FINANCIAL OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 4,744 F2 · kind: The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of RSUs. The sale was to satisfy tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person. Read SEC document |
| September 14, 2024 Filed Sep 17, 2024 22:41 UTC | ANAPTYSBIO, INC ANAB · Entity 4640 | Exercise / conversionRestricted Stock Unit · Derivative | 6,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-24-023549 · form4-09172024_100933.xml · derivative · entry 5 MULROY DENNIS · CIK 0001276840 · CHIEF FINANCIAL OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 6,000 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock award ("RSU") represents a contingent right to receive 1 share of the Issuer's Common Stock upon settlement for no consideration. F4 · derivative.exercise_date: 50% of the total restricted stock units vested on September 14, 2023 and September 14, 2024, subject to the Reporting Person's provision of service to the Issuer on each vesting date. F4 · derivative.expiration_date: 50% of the total restricted stock units vested on September 14, 2023 and September 14, 2024, subject to the Reporting Person's provision of service to the Issuer on each vesting date. Read SEC document |
| September 14, 2024 Filed Sep 17, 2024 22:41 UTC | ANAPTYSBIO, INC ANAB · Entity 4640 | Exercise / conversionCommon Stock | 6,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001415889-24-023549 · form4-09172024_100933.xml · nonDerivative · entry 1 MULROY DENNIS · CIK 0001276840 · CHIEF FINANCIAL OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 6,964 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock award ("RSU") represents a contingent right to receive 1 share of the Issuer's Common Stock upon settlement for no consideration. Read SEC document |
| July 22, 2024 Filed Jul 24, 2024 20:14 UTC | ANAPTYSBIO, INC ANAB · Entity 4640 | GrantCommon Stock · Derivative | 20,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-24-020034 · form4-07242024_080733.xml · derivative · entry 1 MULROY DENNIS · CIK 0001276840 · CHIEF FINANCIAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires not disclosed F1 · derivative.exercise_price: Each performance stock unit ("PSU") represents a contingent right to receive 1 share of the Issuer's Common Stock upon settlement for no consideration. F2 · derivative.exercise_date: Shares earned upon the vesting of a percentage of the PSUs granted to the Reporting Person on July 22, 2024. Each PSU represents a contingent right to receive one share of Issuer common stock upon the Issuer's achievement of certain share price metrics ("Performance Metrics"). 50% of the total number of shares subject to the PSU that achieves the applicable Performance Metrics shall vest on the later of (i) the 1-year anniversary of the achievement of such applicable Performance Metrics and (ii) on July 1, 2026. An additional 50% of the total number of shares subject to the PSU that achieves the applicable Performance Metrics shall vest on the 2-year anniversary of such achievement (but not later than July 1, 2028), subject to the Reporting Person' service to the Issue on each vesting date. F2 · derivative.expiration_date: Shares earned upon the vesting of a percentage of the PSUs granted to the Reporting Person on July 22, 2024. Each PSU represents a contingent right to receive one share of Issuer common stock upon the Issuer's achievement of certain share price metrics ("Performance Metrics"). 50% of the total number of shares subject to the PSU that achieves the applicable Performance Metrics shall vest on the later of (i) the 1-year anniversary of the achievement of such applicable Performance Metrics and (ii) on July 1, 2026. An additional 50% of the total number of shares subject to the PSU that achieves the applicable Performance Metrics shall vest on the 2-year anniversary of such achievement (but not later than July 1, 2028), subject to the Reporting Person' service to the Issue on each vesting date. Read SEC document |
| May 22, 2024 Filed May 24, 2024 20:12 UTC | ANAPTYSBIO, INC ANAB · Entity 4640 | SaleCommon Stock | 1,500 | $23.72 | $35,580.00 |
DisclosureSEC source: 0001415889-24-014463 · form4-05242024_080509.xml · nonDerivative · entry 1 MULROY DENNIS · CIK 0001276840 · CHIEF FINANCIAL OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 964 F1 · kind: The sale reported on this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 26, 2023. F2 · balance_after: Includes shares of Common Stock acquired pursuant to the Issuer's Employee Stock Purchase Plan, for the purchase period through May 15, 2024. Read SEC document |
| January 30, 2024 Filed Feb 1, 2024 22:27 UTC | ANAPTYSBIO, INC ANAB · Entity 4640 | SaleCommon Stock | 3,065 | $23.63 | $72,425.34 |
DisclosureSEC source: 0001415889-24-002204 · form4-02012024_100227.xml · nonDerivative · entry 1 MULROY DENNIS · CIK 0001276840 · CHIEF FINANCIAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 964 F1 · kind: The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $23.325 to $23.77, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth herein. Read SEC document |
| January 08, 2024 Filed Jan 10, 2024 00:06 UTC | ANAPTYSBIO, INC ANAB · Entity 4640 | SaleCommon Stock | 2,180 | $21.81 | $47,545.80 |
DisclosureSEC source: 0001209191-24-001278 · doc4.xml · nonDerivative · entry 2 MULROY DENNIS · CIK 0001276840 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,029 F2 · kind: The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of RSUs. The sale was to satisfy tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person. Read SEC document |
| January 06, 2024 Filed Jan 10, 2024 00:06 UTC | ANAPTYSBIO, INC ANAB · Entity 4640 | Exercise / conversionRestricted Stock Unit · Derivative | 5,245 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-24-001278 · doc4.xml · derivative · entry 3 MULROY DENNIS · CIK 0001276840 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 15,735 Underlying: Common Stock · 5,245 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock award ("RSU") represents a contingent right to receive 1 share of the Issuer's Common Stock upon settlement for no consideration. F3 · derivative.exercise_date: The RSUs vests as to 25% of the total RSUs annually commencing on January 6, 2024 until fully vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date. F3 · derivative.expiration_date: The RSUs vests as to 25% of the total RSUs annually commencing on January 6, 2024 until fully vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date. Read SEC document |
| January 06, 2024 Filed Jan 10, 2024 00:06 UTC | ANAPTYSBIO, INC ANAB · Entity 4640 | Exercise / conversionCommon Stock | 5,245 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-24-001278 · doc4.xml · nonDerivative · entry 1 MULROY DENNIS · CIK 0001276840 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,209 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock award ("RSU") represents a contingent right to receive 1 share of the Issuer's Common Stock upon settlement for no consideration. Read SEC document |
| January 03, 2024 Filed Jan 5, 2024 21:54 UTC | ANAPTYSBIO, INC ANAB · Entity 4640 | GrantRestricted Stock Unit · Derivative | 33,170 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-24-001046 · doc4.xml · derivative · entry 2 MULROY DENNIS · CIK 0001276840 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 33,170 Underlying: Common Stock · 33,170 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock award ("RSU") represents a contingent right to receive 1 share of the Issuer's Common Stock upon settlement for no consideration. F3 · derivative.exercise_date: The RSUs vests as to 25% of the total RSUs annually commencing on January 3, 2025 until fully vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date. F3 · derivative.expiration_date: The RSUs vests as to 25% of the total RSUs annually commencing on January 3, 2025 until fully vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date. Read SEC document |
| January 03, 2024 Filed Jan 5, 2024 21:54 UTC | ANAPTYSBIO, INC ANAB · Entity 4640 | GrantStock Option (right to buy) · Derivative | 90,780 | $0.00 Strike: $21.19 | $0.00 |
DisclosureSEC source: 0001209191-24-001046 · doc4.xml · derivative · entry 1 MULROY DENNIS · CIK 0001276840 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 90,780 Underlying: Common Stock · 90,780 shares Expires 2034-01-02 F1 · derivative.exercise_date: The stock option vests as to 25% of the total shares on January 3, 2025, and thereafter vests as to 1/48 of the total shares monthly until fully vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date. Read SEC document |
| September 18, 2023 Filed Sep 18, 2023 22:12 UTC | ANAPTYSBIO, INC ANAB · Entity 4640 | SaleCommon Stock | 3,895 | $19.32 | $75,236.60 |
DisclosureSEC source: 0001209191-23-049808 · doc4.xml · nonDerivative · entry 3 MULROY DENNIS · CIK 0001276840 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 964 F3 · kind: The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $19.145 to $19.60, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth herein. Read SEC document |
| September 14, 2023 Filed Sep 18, 2023 22:12 UTC | ANAPTYSBIO, INC ANAB · Entity 4640 | Exercise / conversionRestricted Stock Unit · Derivative | 6,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-049808 · doc4.xml · derivative · entry 4 MULROY DENNIS · CIK 0001276840 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,000 Underlying: Common Stock · 6,000 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock award ("RSU") represents a contingent right to receive 1 share of the Issuer's Common Stock upon settlement for no consideration. F5 · derivative.exercise_date: 50% of the total restricted stock units vest on September 14, 2023 and September 14, 2024, subject to the Reporting Person's provision of service to the Issuer on each vesting date. F5 · derivative.expiration_date: 50% of the total restricted stock units vest on September 14, 2023 and September 14, 2024, subject to the Reporting Person's provision of service to the Issuer on each vesting date. Read SEC document |
| September 14, 2023 Filed Sep 18, 2023 22:12 UTC | ANAPTYSBIO, INC ANAB · Entity 4640 | SaleCommon Stock | 2,105 | $19.48 | $41,005.40 |
DisclosureSEC source: 0001209191-23-049808 · doc4.xml · nonDerivative · entry 2 MULROY DENNIS · CIK 0001276840 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,859 F2 · kind: The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of RSUs. The sale was to satisfy tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person. Read SEC document |
| September 14, 2023 Filed Sep 18, 2023 22:12 UTC | ANAPTYSBIO, INC ANAB · Entity 4640 | Exercise / conversionCommon Stock | 6,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-23-049808 · doc4.xml · nonDerivative · entry 1 MULROY DENNIS · CIK 0001276840 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,964 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock award ("RSU") represents a contingent right to receive 1 share of the Issuer's Common Stock upon settlement for no consideration. Read SEC document |
| January 06, 2023 Filed Jan 11, 2023 00:09 UTC | ANAPTYSBIO, INC ANAB · Entity 4640 | GrantRestricted Stock Unit · Derivative | 20,980 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-002883 · doc4.xml · derivative · entry 2 MULROY DENNIS · CIK 0001276840 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,980 Underlying: Common Stock · 20,980 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock award ("RSU") represents a contingent right to receive 1 share of the Issuer's Common Stock upon settlement for no consideration. F3 · derivative.exercise_date: The RSUs vests as to 25% of the total RSUs annually commencing on January 6, 2024 until fully vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date. F3 · derivative.expiration_date: The RSUs vests as to 25% of the total RSUs annually commencing on January 6, 2024 until fully vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date. Read SEC document |
| January 06, 2023 Filed Jan 11, 2023 00:09 UTC | ANAPTYSBIO, INC ANAB · Entity 4640 | GrantStock Option (right to buy) · Derivative | 57,260 | $0.00 Strike: $23.23 | $0.00 |
DisclosureSEC source: 0001209191-23-002883 · doc4.xml · derivative · entry 1 MULROY DENNIS · CIK 0001276840 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 57,260 Underlying: Common Stock · 57,260 shares Expires 2033-01-05 F1 · derivative.exercise_date: The stock option vests as to 25% of the total shares on January 6, 2024, and thereafter vests as to 1/48 of the total shares monthly until fully vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date. Read SEC document |
| September 14, 2022 Filed Sep 16, 2022 21:06 UTC | ANAPTYSBIO, INC ANAB · Entity 4640 | GrantRestricted Stock Unit · Derivative | 12,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-050350 · doc4.xml · derivative · entry 1 MULROY DENNIS · CIK 0001276840 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,000 Underlying: Common Stock · 12,000 shares Expires not disclosed F1 · derivative.exercise_price: Represents a one-time retention grant of restricted stock units ("RSUs"). Each RSU represents a contingent right to receive 1 share of the Issuer's Common Stock upon settlement for no consideration. F2 · derivative.exercise_date: 50% of the total RSUs vest on September 14, 2023 and September 14, 2024, subject to the Reporting Person's provision of service to the Issuer on each vesting date. F2 · derivative.expiration_date: 50% of the total RSUs vest on September 14, 2023 and September 14, 2024, subject to the Reporting Person's provision of service to the Issuer on each vesting date. F3 · balance_after: In addition to the remaining options to purchase 12,000 shares of common stock as set forth in Table II above, the Reporting Person also holds (i) additional options to purchase up to an aggregate of 215,600 shares of common stock, which options vest according to their terms, and (ii) 964 shares of common stock held directly. Read SEC document |
| June 23, 2022 Filed Jun 27, 2022 23:06 UTC | ANAPTYSBIO, INC ANAB · Entity 4640 | GrantStock Option (right to buy) · Derivative | 10,000 | $0.00 Strike: $29.70 | $0.00 |
DisclosureSEC source: 0001209191-22-039534 · doc4.xml · derivative · entry 1 MULROY DENNIS · CIK 0001276840 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Stock · 10,000 shares Expires 2031-02-09 F1 · derivative.exercise_date: On February 10, 2021, the reporting person was granted a performance-based option to purchase 10,000 shares of the Issuer's common stock, subject to the achievement of certain corporate performance criteria and the reporting person's continued service to the Issuer upon achievement thereof. The performance criteria were achieved on the date in Column 3, resulting in the vesting of the entire award. F2 · balance_after: In addition to the remaining options to purchase 10,000 shares of common stock as set forth in Table II above, the Reporting Person also holds (i) additional options to purchase up to an aggregate of 205,600 shares of common stock, which options vest according to their terms, and (ii) 964 shares of common stock held directly. Read SEC document |
| February 10, 2022 Filed Feb 14, 2022 21:45 UTC | ANAPTYSBIO, INC ANAB · Entity 4640 | GrantStock Option (right to buy) · Derivative | 70,000 | $0.00 Strike: $30.44 | $0.00 |
DisclosureSEC source: 0001209191-22-009329 · doc4.xml · derivative · entry 1 MULROY DENNIS · CIK 0001276840 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 70,000 Underlying: Common Stock · 70,000 shares Expires 2032-02-09 F1 · derivative.exercise_date: The stock option vests and becomes exercisable as to 25% of the shares subject to the option on February 10, 2023, and thereafter vests as to 1/48th of the shares in equal monthly installments, until such time as the option is 100% vested, subject to the continuing employment of the Reporting Person on each vesting date. F2 · balance_after: In addition to the remaining options to purchase 70,000 shares of common stock as set forth in Table II above, the Reporting Person also holds (i) additional options to purchase up to an aggregate of 135,600 shares of common stock, which options vest according to their terms, and (ii) 964 shares of common stock held directly. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.